Systemic sclerosis (scleroderma) trials in China

In China 64 Also abroad 213

64 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
Where
Beijing, Chongqing, Guangzhou, Jinan, Lanzhou, Shanghai, Shenzhen
Age
5 years to 80 years
People
1,072 worldwide
Run by
AstraZeneca
See details and how to joinNCT07691970
Phase 1Taking people
A Study of ATG-201 in Adult Participants With Autoimmune Diseases
Where
Beijing, Bengbu, Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Linyi, Luoyang, Nanjing, Shanghai, Suzhou, Taiyuan, Wuhan, Xiamen, Xi'an, Zhengzhou
Age
18 years and over
People
149
Run by
Antengene Biologics Limited
See details and how to joinNCT07732309
No phaseTaking people
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
Where
Shanghai
Age
18 years to 65 years
People
6
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06379646
Phase 1Taking people
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
Where
Beijing
Age
18 years to 65 years
People
12
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT06978647
Phase 1Taking people
A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Where
Hefei
Age
18 years to 65 years
People
18
Run by
China Immunotech (Beijing) Biotechnology Co., Ltd.
See details and how to joinNCT07104721
Phase 1Taking people
A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 65 years
People
12
Run by
Therorna
See details and how to joinNCT07413341
Phase 3Taking people
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
Where
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenzhen, Sichuan, Tianjin, Wenzhou, Wuhan, Xiamen, Xuzhou, Zhuzhou
Age
18 years and over
People
448 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00
Phase 1/2Taking people
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
Where
Beijing, Guangzhou, Henan, Nanchang, Nanjing, Pingxiang
Age
18 years to 65 years
People
44 worldwide
Run by
Prolium Bioscience, Inc
See details and how to joinNCT07641634
Early phase 1Taking people
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 80 years
People
10
Run by
Peking University Third Hospital
See details and how to joinNCT07301164
No phaseTaking people
Clinical Cohort Study of Systemic Sclerosis
Where
Beijing
Age
Up to 100 years
People
150
Run by
Peking University Third Hospital
See details and how to joinNCT07836361
Phase 1/2Taking people
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 80 years
People
9
Run by
Peking University Third Hospital
See details and how to joinNCT06828042
Phase 3Taking people
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Where
Beijing, Chengdu, Hangzhou, Mianyang, Shanghai, Shenyang, Zhuzhou
Age
18 years and over
People
514 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06716606
Phase 2/3Taking people
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Where
Beijing, Changchun, Chengdu, Luzhou, Mianyang, Nanjing, Nanning, Shanghai, Shenyang, Xi'an, Zhuzhou
Age
18 years and over
People
300 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT05878717 · EU 2023-503219-14-01
Early phase 1Not yet taking people in China
Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
Where
Beijing
Age
18 years to 80 years
People
18
Run by
Qiubai Li
See details and how to joinNCT07806045
No phaseEnrolling by invitation
Mass Spectrometry-based Immune Profiling in Autoimmune Diseases
Where
Beijing
Age
18 years and over
People
500
Run by
Peking University People's Hospital
See details and how to joinNCT07188285
Phase 1Taking people
Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs）
Where
Hefei
Age
18 years to 69 years
People
30
Run by
Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT06801119
Phase 1Not yet taking people in China
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
Where
Hefei
Age
18 years to 69 years
People
12
Run by
Shenzhen MagicRNA Biotechnology Co., Ltd
See details and how to joinNCT07523282
Phase 2Not yet taking people in China
A Phase II Study of TollB-001 Tablets in Systemic Sclerosis
Where
Beijing
Age
18 years to 70 years
People
36
Run by
Toll Biotech Co. Ltd. (Beijing)
See details and how to joinNCT07745725
Phase 1/2Taking people
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
Where
Beijing
Age
10 years to 65 years
People
45
Run by
Beijing GoBroad Hospital
See details and how to joinNCT06947460
Early phase 1Not yet taking people in China
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
Where
Shanghai
Age
18 years to 70 years
People
30
Run by
Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07596680
Early phase 1Taking people
MTS109 in Patients With Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 65 years
People
15
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07526350
Phase 1Not yet taking people in China
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Where
Qingdao
Age
18 years to 70 years
People
18
Run by
The Affiliated Hospital of Qingdao University
See details and how to joinNCT07676266
Early phase 1Not yet taking people in China
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
Where
Hangzhou, Nanjing
Age
5 years to 20 years
People
30
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07674147
Early phase 1Taking people
CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease
Where
Hangzhou
Age
3 years and over
People
15
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07586267
No phaseTaking people
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
Where
Nanjing
Age
18 years to 70 years
People
72
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07558850